Vivus
As of the edition of 20 October 2026, Vivus runs 6 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Vivus was bankrupt in 2020.
- Vivus Llc: bankrupt in 2020
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 2 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Alprostadil | none listed | 2 |
| Pancrelipase | Ended 2008 (computed from the first US licence) | 0 |
| Avanafil | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Vivus needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 15 trials led
- Urinary and reproductive: 14 trials led
- Nutrition and metabolism: 8 trials led